Top

Published in:

04-01-2024 | Prostate Cancer

Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy

Authors: Anthony V. Serritella, MD, Maha Hussain, MD, FACP, FASCO

Published in: Current Treatment Options in Oncology | Issue 3/2024

Opinion Statement

Treatment for metastatic hormone–sensitive prostate cancer has undergone significant evolution in recent years, leading to substantial improvements in overall survival. Men are living longer than ever before with a median survival now which is almost 6 years. The timing and extent of metastatic disease combined with individual patient factors helps treatment recommendation of doublet therapy including androgen deprivation (ADT) plus either chemotherapy or androgen receptor signaling inhibition (ARSI) or triplet therapy with ADT+ARSI+chemotherapy. New treatments must continue to be developed to enhance survival with goals of cure. Better biomarkers that allow for more effective treatments will enhance disease control, quality of life, and survival.

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.CrossRefPubMed

• Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, et al. Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment. Am Soc Clin Oncol Educ Book. 2023;43:e390166. https://doi.org/10.1200/edbk_390166. This manuscript provides a useful overview of the various studies which have influenced treatment practices for mHSPC.CrossRefPubMed

Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, et al. Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open. 2022;5(3): e222246. https://doi.org/10.1001/jamanetworkopen.2022.2246.CrossRefPubMedPubMedCentral

Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016;19(4):395–7. https://doi.org/10.1038/pcan.2016.30.CrossRefPubMed

•• Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New England Journal of Medicine. 2015;373(8):737–46. https://doi.org/10.1056/NEJMoa1503747. This is a landmark phase III study that provided level 1 evidence for the combination of docetaxel-based chemotherapy added to androgen deprivation in prostate cancer.CrossRefPubMed

Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–7. https://doi.org/10.1200/jco.2017.75.3657.CrossRefPubMedPubMedCentral

Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy. ESMO Open. 2023;8(2):101194. https://doi.org/10.1016/j.esmoop.2023.101194.

Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012;118(12):3062–70. https://doi.org/10.1002/cncr.26392.CrossRefPubMed

Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018;78(12):889–95. https://doi.org/10.1002/pros.23645.CrossRefPubMedPubMedCentral

10.

Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119–34. https://doi.org/10.1016/j.annonc.2020.06.011.CrossRefPubMed

11.

Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med. 2017;7(9). https://doi.org/10.1101/cshperspect.a030452.

12.

• Gravis G, Boher J-M, Joly F, Soulié M, Albiges L, Priou F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. European Urology. 2016;70(2):256–62. https://doi.org/10.1016/j.eururo.2015.11.005. This is combination analysis of two phase III studies CHAARTED and GETUG-AFU15 taking into account disease volume.

13.

Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30(12):1992–2003. https://doi.org/10.1093/annonc/mdz396.CrossRefPubMedPubMedCentral

14.

Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nature Reviews Urology. 2021;18(2):79–92. https://doi.org/10.1038/s41585-020-00400-w.CrossRefPubMed

15.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine. 2004;351(15):1502–12. https://doi.org/10.1056/NEJMoa040720.CrossRefPubMed

16.

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20. https://doi.org/10.1056/NEJMoa041318.CrossRefPubMed

17.

Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2013;14(2):149–58. https://doi.org/10.1016/S1470-2045(12)70560-0.CrossRefPubMed

18.

Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol. 2018;73(6):847–55. https://doi.org/10.1016/j.eururo.2018.02.001.CrossRefPubMedPubMedCentral

19.

• James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77. https://doi.org/10.1016/s0140-6736(15)01037-5. This is primary result of the phase III study that provided additional support for ADT + docetaxel in mHSPC.

20.

• Vale CL, Fisher DJ, Godolphin PJ, Rydzewska LH, Boher J-M, Burdett S, et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. The Lancet Oncology. 2023;24(7):783–97. https://doi.org/10.1016/S1470-2045(23)00230-9. This meta-analysis provided useful analysis demonstrating that the addition of docetaxel to hormone therapy is best suited to patients with poorer prognosis for metastatic, hormone-sensitive prostate cancer based on a high volume of disease and potentially the bulkiness of the primary tumour.CrossRefPubMed

21.

James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer. 2022;151(3):422–34. https://doi.org/10.1002/ijc.34018.CrossRefPubMedPubMedCentral

22.

•• Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine. 2017;377(4):352–60. https://doi.org/10.1056/NEJMoa1704174. This phase III study demonstrated that the addition of abiraterone acetate and prednisone to androgen-deprivation therapy significantly increased overall survival and radiographic progression-free survival in men with newly diagnosed, metastatic, castration-sensitive prostate cancer irrespective of disease volume.CrossRefPubMed

23.

• Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700. https://doi.org/10.1016/s1470-2045(19)30082-8. This is the final OS analysis of reference #22.CrossRefPubMed

24.

• Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine. 2019;381(2):121–31. https://doi.org/10.1056/NEJMoa1903835. This is phase III study demonstrated that enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression. The enzalutamide group had a higher incidence of seizures and other toxic effects, especially among those treated with early docetaxel.CrossRefPubMed

25.

Davis ID, Martin AJ, Zielinski RR, Thomson A, Tan TH, Sandhu S, et al. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). Journal of Clinical Oncology. 2022;40(17_suppl):LBA5004-LBA. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA5004.

26.

• Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. The Lancet Oncology. 2023;24(4):323–34. https://doi.org/10.1016/S1470-2045(23)00063-3. This was the planned primary overall survival analysis of ENZAMET analysis accounting for different subgroups of patients.CrossRefPubMed

27.

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–86. https://doi.org/10.1200/jco.19.00799.CrossRefPubMedPubMedCentral

28.

• Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616–22. https://doi.org/10.1200/jco.22.00193. Updated results on survival with enzalutamide.CrossRefPubMedPubMedCentral

29.

• Chi KN, Agarwal N, Bjartell A, Chung BH, de Santana Pereira, Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. New England Journal of Medicine. 2019;381(1):13–24. https://doi.org/10.1056/NEJMoa1903307. In this trial involving patients with mHSPC, overall survival and radiographic progression–free survival were significantly longer with the addition of apalutamide to ADT than with placebo plus ADT, and the side-effect profile did not differ substantially between the two groups.CrossRefPubMed

30.

• Chi KN, Chowdhury S, Bjartell A, Chung BH, de Santana Pereira, Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294–303. https://doi.org/10.1200/jco.20.03488. The final analysis of TITAN confirmed that, despite crossover, apalutamide plus ADT improved OS, delayed castration resistance, maintained health-related quality of life, and had a consistent safety profile in a broad population of patients with mHSPC. OS benefits was regardless of disease volume.CrossRefPubMed

31.

Merseburger AS, Agarwal N, Bhaumik A, Lefresne F, Karsh LI, Pereira de Santana Gomes AJ, et al. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.113290.

32.

Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29(5):1235–48. https://doi.org/10.1093/annonc/mdy072.CrossRefPubMedPubMedCentral

33.

Feyerabend S, Saad F, Li T, Ito T, Diels J, Van Sanden S, et al. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis. European Journal of Cancer. 2018;103:78–87. https://doi.org/10.1016/j.ejca.2018.08.010.CrossRefPubMed

34.

Rush HL, Murphy L, Morgans AK, Clarke NW, Cook AD, Attard G, et al. Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial. J Clin Oncol. 2022;40(8):825–36. https://doi.org/10.1200/jco.21.00728.CrossRefPubMed

35.

•• Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 & #xd7; 2 factorial design. The Lancet. 2022;399(10336):1695–707. https://doi.org/10.1016/S0140-6736(22)00367-1. This is a landmark phase III trial which demonstrated that triplet therapy with androgen deprivation therapy, docetaxel, and abiraterone in de novo metastatic castration-sensitive prostate cancer improved overall survival and radiographic progression-free survival.CrossRef

36.

•• Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. New England Journal of Medicine. 2022;386(12):1132–42. https://doi.org/10.1056/NEJMoa2119115. This is a landmark phase III trial that demonstrated that in patients with mHSPC, overall survival was significantly longer with the triplet of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus androgen-deprivation therapy and docetaxel, and the addition of darolutamide led to improvement in key secondary end points.CrossRefPubMed

37.

•• Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. Journal of Clinical Oncology. 2023;41(20):3595–607. https://doi.org/10.1200/jco.23.00041. This is a secondary analysis of reference #36 that demonstrates that in patients with high-volume and high-risk/low-risk metastatic hormone-sensitive prostate cancer, treatment intensification with darolutamide, androgen-deprivation therapy, and docetaxel increased OS with a similar AE profile in the subgroups, consistent with the overall population.CrossRefPubMed

38.

• Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. The Lancet. 2018;392(10162):2353–66. https://doi.org/10.1016/S0140-6736(18)32486-3. This trial demonstrated that radiotherapy to the prostate did not improve overall survival for unselected patients with newly diagnosed metastatic prostate cancer. In LV disease patients, addition of RT to standard of care resulted in a significant survival benefit (HR 0.64, 95% CI 0.52-0.79) with acceptable toxicity. There was no benefit in HV disease patients (HR 1.1, 95% CI 0.96-1.28).CrossRef

39.

McManus HD, Armstrong AJ. The past, present, and future of treatment intensification for metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2023;41(20):3576–9. https://doi.org/10.1200/jco.23.00323.CrossRefPubMed

40.

Wala J, Nguyen P, Pomerantz M. Early treatment intensification in metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2023;41(20):3584–90. https://doi.org/10.1200/jco.23.00723.CrossRefPubMed

41.

• Boevé LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75(3):410–8. https://doi.org/10.1016/j.eururo.2018.09.008. This reference demonstrated that additional radiotherapy did not improve overall survival in mHSPC patients. While the overall analysis of HORRAD (comparing ADT vs. ADT+RT) did not show a survival benefit from the addition of RT in all-comers, in patients with <5 metastases, there was a trend towards a survival benefit.CrossRefPubMed

42.

Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncology. 2020;6(5):650–9. https://doi.org/10.1001/jamaoncol.2020.0147.CrossRefPubMedPubMedCentral

43.

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–53. https://doi.org/10.1200/jco.2017.75.4853.CrossRefPubMed

44.

Bossi A, Foulon S, Maldonado X, Sargos P, McDermott RS, Flechon A, et al. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2x2 design. Journal of Clinical Oncology. 2023;41(17_suppl):LBA5000-LBA. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA5000.

45.

Swami U, Hong A, El-Chaar NN, Nimke D, Ramaswamy K, Bell EJ, et al. Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database. Journal of Clinical Oncology. 2021;39(15_suppl):5072-https://doi.org/10.1200/JCO.2021.39.15_suppl.5072.

46.

George DJ, Agarwal N, Ramaswamy K, Sandin R, Russell D, Hong A, et al. 616P Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): a Medicare database analysis. Annals of Oncology. 2021;32:S655–6. https://doi.org/10.1016/j.annonc.2021.08.1129.CrossRef

47.

Heath EI, Dyson GE, Cackowski FC, Hafron J, Powell I. Treatment intensification patterns and utilization in patients with metastatic castration-sensitive prostate cancer. Clin Genitourin Cancer. 2022;20(6):524–32. https://doi.org/10.1016/j.clgc.2022.06.017.CrossRefPubMed

48.

Stopsack KH, Nandakumar S, Wibmer AG, Haywood S, Weg ES, Barnett ES, et al. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin Cancer Res. 2020;26(13):3230–8. https://doi.org/10.1158/1078-0432.Ccr-20-0168.CrossRefPubMedPubMedCentral

49.

Gilson C, Ingleby F, Gilbert DC, Parry MA, Atako NB, Ali A, et al. Genomic profiles of de novo high- and low-volume metastatic prostate cancer: results from a 2-stage feasibility and prevalence study in the STAMPEDE trial. JCO Precision Oncology. 2020;4:882–97. https://doi.org/10.1200/po.19.00388.CrossRefPubMed

50.

Grist E, Friedrich S, Brawley C, Mendes L, Parry M, Ali A, et al. Accumulation of copy number alterations and clinical progression across advanced prostate cancer. Genome Med. 2022;14(1):102. https://doi.org/10.1186/s13073-022-01080-4.CrossRefPubMedPubMedCentral

51.

Agarwal N, Lucas J, Aguilar-Bonavides C, Thomas S, Gormley M, Chowdhury S, et al. Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN. Journal of Clinical Oncology. 2022;40(16_suppl):5066. https://doi.org/10.1200/JCO.2022.40.16_suppl.5066.CrossRef

52.

Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, et al. SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer. Clin Cancer Res. 2022;28(22):4917–25. https://doi.org/10.1158/1078-0432.Ccr-22-2228.CrossRefPubMed

53.

Nizialek E, Lim SJ, Wang H, Isaacsson Velho P, Yegnasubramanian S, Antonarakis ES. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer. Prostate. 2021;81(9):572–9. https://doi.org/10.1002/pros.24135.CrossRefPubMed

54.

Deek MP, Van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL, et al. The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited. Eur Urol. 2021;80(5):632–40. https://doi.org/10.1016/j.eururo.2020.12.040.CrossRefPubMedPubMedCentral

55.

Palmbos PL, Daignault-Newton S, Tomlins SA, Agarwal N, Twardowski P, Morgans AK, et al. A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone-sensitive prostate cancer. Clin Cancer Res. 2021;27(11):3017–27. https://doi.org/10.1158/1078-0432.Ccr-21-0024.CrossRefPubMedPubMedCentral

56.

Sutera P, Song Y, Van der Eecken K, Shetty AC, English K, Hodges T, et al. Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer. Eur Urol. 2023;84(6):531–5. https://doi.org/10.1016/j.eururo.2023.04.025.CrossRefPubMed

57.

Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. https://doi.org/10.1007/s00259-013-2525-5.CrossRefPubMed

58.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20(9):1286–94. https://doi.org/10.1016/s1470-2045(19)30415-2.CrossRefPubMedPubMedCentral

59.

de Galiza Barbosa F, Queiroz MA, Nunes RF, Costa LB, Zaniboni EC, Marin JFG, et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20(1):23. https://doi.org/10.1186/s40644-020-00300-7.CrossRef

60.

Hussain M, Carducci MA, Clarke N, Fenton SE, Fizazi K, Gillessen S, et al. Evolving role of prostate-specific membrane antigen-positron emission tomography in metastatic hormone-sensitive prostate cancer: more questions than answers? J Clin Oncol. 2022;40(26):3011–4. https://doi.org/10.1200/jco.22.00208.CrossRefPubMed

61.

Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine. 1989;321(7):419–24. https://doi.org/10.1056/nejm198908173210702.CrossRefPubMed

62.

Rathkopf DE, Chi KN, Olmos D, Cheng HH, Agarwal N, Graff JN, et al. AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). Journal of Clinical Oncology. 2021;39(6_suppl):TPS176-TPS. https://doi.org/10.1200/JCO.2021.39.6_suppl.TPS176.

63.

Agarwal N, Azad A, Fizazi K, Mateo J, Matsubara N, Shore ND, et al. Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC). Journal of Clinical Oncology. 2022;40(6_suppl):TPS221-TPS. https://doi.org/10.1200/JCO.2022.40.6_suppl.TPS221.

64.

Sartor AO, Tagawa ST, Saad F, Bono JSD, Feng FY, Fizazi K, et al. PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology. 2022;40(6_suppl):TPS210-TPS. https://doi.org/10.1200/JCO.2022.40.6_suppl.TPS210.

Title: Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy
Authors: Anthony V. Serritella, MD
Maha Hussain, MD, FACP, FASCO
Publication date: 04-01-2024
Publisher: Springer US
Keywords: Prostate Cancer
Prostate Cancer
Enzalutamide
Androgens
Apalutamide
Published in: Current Treatment Options in Oncology / Issue 3/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-023-01173-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Opinion Statement

Please log in to get access to this content

Other articles of this Issue 3/2024

Antiepileptic strategies for patients with brain tumors

Targeting BRCA and PALB2 in Pancreatic Cancer

Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer

Steroid Premedication and Monoclonal Antibody Therapy: Should We Reconsider?

Updates on Management of Biochemical Recurrent Prostate Cancer

Hypnosis for Symptom Management in Adult Cancer Patients: What is the Evidence?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer